Antibodies directed against endogenous and exogenous citrullinated antigens pre-date the onset of rheumatoid arthritis

• Main Authors: Johansson, Linda, Pratesi, Federico, Brink, Mikael, Ärlestig, Lisbeth, D’Amato, Claudia, Bartaloni, Debora, Migliorini, Paola, Rantapää-Dahlqvist, Solbritt
• Format: Article in Journal/Newspaper
• Language: unknown
• Published: Figshare 2016
• Subjects: Biochemistry; Genetics; FOS Biological sciences; Physiology; Biotechnology; Ecology; Immunology; FOS Clinical medicine; Developmental Biology; Cancer; Northern Sweden
• Online Access: https://dx.doi.org/10.6084/m9.figshare.c.3640808.v1; https://figshare.com/collections/Antibodies_directed_against_endogenous_and_exogenous_citrullinated_antigens_pre-date_the_onset_of_rheumatoid_arthritis/3640808/1

Abstract Background Anti-citrullinated-peptide antibodies (ACPA) have been detected in individuals with developing rheumatoid arthritis (RA) before the onset of symptom, with an initially limited spectrum of reactivities that gradually broadens. The aim was to analyze the evolution of ACPA response pre-dating symptom onset, using four selected citrullinated exogenous and endogenous antigens. Methods A cohort of 521 individuals sampled before symptoms of RA appeared and 272 population controls were identified from the Biobank of Northern Sweden; 241 samples from patients with early RA were also collected. ACPA were detected by ELISA on viral citrullinated peptides (VCP) derived from Epstein-Barr-virus nuclear antigen (EBNA)1 and EBNA2 (VCP1 and VCP2) and histone-4-derived citrullinated peptides (HCP1 and HCP2). Results In pre-symptomatic individuals vs. patients with early RA, anti-VCP1 antibodies were detected in 10.4 % vs. 36.1 %, anti-VCP2 in 17.1 % vs. 52.3 %, anti-HCP1 in 10.2 % vs. 37.3 %, and anti-HCP2 in 16.3 % vs. 48.5 %, respectively. Anti-VCP and anti-HCP concentrations were significantly increased in pre-symptomatic individuals vs. controls (p